A recent study into the use of anti depressants has confirmed the suspicion that Viagra can help improve the sex performance of women on antidepressants. The study was published in the he Journal of the American Medical Association. Developed by the pharmaceutical company Pfizer, Viagra is particularly popular in the treatment of male erectile dysfunction (impotence) and pulmonary arterial hypertension (PAH).
The study released by U.S researcher on Tuesday reveals that women who took Viagra were less likely to have sexual side effects compared to those who took placebo. Depression has been linked to sexual dysfunction in some cases. It is thought that many women abandon drugs and resort to treating depression.
The doctors who conducted the study, from the University Of New Mexico School Of Medicine acknowledge that between 30 to 70 percent of depression treatment is related to sexual dysfunction.
Whereas Viagra has always been said to help depressed women, the latest study is the first of its kind that has scientific proofs.
In a combined statement with colleagues, Dr. H. George Nurnberg of the University of Mexico said that “By treating this bothersome treatment-associated adverse effect … patients can remain antidepressant-adherent, reduce the current high rates of premature medication discontinuation, and improve depression disease management outcomes.”
Te research funded by Pfizer Inc, maker of Viagra studied a group of 98 women with an average age of 37 years who reported sexual dysfunction. All the women were all on antidepressants and had shown lack of sexual orgasm or arousal.
The researchers found that only 28% of women taking Viagra showed no improvement compared to 73% of women taking a placebo. The study also reported very minor effects.
Sexual dysfunction is commonly linked with using antidepressants, including selective and non selective serotonin reuptake inhibitors.
The sale of Viagra has been dwindling in recent years. Viagra has almost a Markey share of 92 percent in the year 2000.However, with the introduction of competitors like Cialis and Levitra, along with other counterfeits and clones, the market share reduced drastically to 50 percent. The recent study will no doubt increase the sale of the popular Viagra pills.
понедельник, 27 декабря 2010 г.
четверг, 23 декабря 2010 г.
Priapism Responds to New Treatment
Priapism, which many may know better as an erection that lasts longer than four hours, has responded well to a new treatment tested by researchers at The University of Texas Medical School at Houston. At this point, men who develop priapism have few treatment choices for this painful condition.
Men are warned about the possibility of priapism every time they hear a commercial for prescription medication taken to treat erectile dysfunction (ED), yet the term for this rare side effect of ED drugs is seldom used. Priapism develops when blood in the penis becomes trapped and cannot drain out. The condition can occur in males of any age, including newborns, but it is most common between the ages of 5 and 10 years and 20 to 50 years. It is highly associated with leukemia, sickle cell disease, and other blood disorders.
If priapism is not treated immediately, it can result in penile fibrosis, a condition that involves scarring and permanent erectile dysfunction. Thus the announcement that a new treatment could offer a solution can be encouraging for the thousands of men who are afflicted by this condition. The new treatment is actually a novel use for an FDA-approved (Food and Drug Administration) drug called polyethylene glycol-linked adenosine deaminase (PEG-ADA), which is used to treat people who have a deficiency of adenosine deaminase enzyme (ADA). People who are ADA deficient have a condition called Severe Combined Immunodeficiency Disease.
Researchers at The University of Texas propose that priapism is associated with elevated levels of adenosine, a finding they made during previous research in ADA-deficient mice that had long-lasting spontaneous erections. In that study they showed they could prevent and treat priapism in mice. In this latest study, the investigators used PEG-ADA in a group of mice with sickle cell disease features and another group with ADA enzyme deficiency and showed they could prevent penile fibrosis.
Men who have sickle cell disease have a 40 percent chance of developing priapism. The current treatment options for priapism include pain control medication, hydration, and surgery. None of these choices are especially effective. Introduction of a medication that would prevent or treat this condition would be most welcome.
Men are warned about the possibility of priapism every time they hear a commercial for prescription medication taken to treat erectile dysfunction (ED), yet the term for this rare side effect of ED drugs is seldom used. Priapism develops when blood in the penis becomes trapped and cannot drain out. The condition can occur in males of any age, including newborns, but it is most common between the ages of 5 and 10 years and 20 to 50 years. It is highly associated with leukemia, sickle cell disease, and other blood disorders.
If priapism is not treated immediately, it can result in penile fibrosis, a condition that involves scarring and permanent erectile dysfunction. Thus the announcement that a new treatment could offer a solution can be encouraging for the thousands of men who are afflicted by this condition. The new treatment is actually a novel use for an FDA-approved (Food and Drug Administration) drug called polyethylene glycol-linked adenosine deaminase (PEG-ADA), which is used to treat people who have a deficiency of adenosine deaminase enzyme (ADA). People who are ADA deficient have a condition called Severe Combined Immunodeficiency Disease.
Researchers at The University of Texas propose that priapism is associated with elevated levels of adenosine, a finding they made during previous research in ADA-deficient mice that had long-lasting spontaneous erections. In that study they showed they could prevent and treat priapism in mice. In this latest study, the investigators used PEG-ADA in a group of mice with sickle cell disease features and another group with ADA enzyme deficiency and showed they could prevent penile fibrosis.
Men who have sickle cell disease have a 40 percent chance of developing priapism. The current treatment options for priapism include pain control medication, hydration, and surgery. None of these choices are especially effective. Introduction of a medication that would prevent or treat this condition would be most welcome.
Подписаться на:
Сообщения (Atom)